Home » Healthcare » Flowable Hemostats Market

Flowable Hemostats Market By Material (Porcine Gelatin, Bovine Gelatin); By Application (General Surgery, Cardiac Surgery, Vascular Surgery, Neuro and Spine Surgery, Orthopedic Surgery, Others); By End-user (Hospitals, Ambulatory Surgery Centers, Clinics); By Region – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Price: $4999

Published: | Report ID: 36279 | Report Format : PDF
REPORT ATTRIBUTE DETAILS
Historical Period  2019-2022
Base Year  2023
Forecast Period  2024-2032
Flowable Hemostats Market Size 2023  USD 1104.4 Million
Flowable Hemostats Market, CAGR  6.98%
Flowable Hemostats Market Size 2032  USD 3097.6 Million

Market Overview:

The Flowable Hemostats Market is on a trajectory of substantial growth, anticipated to surge from $1104.4 million in 2023 to $3097.6 million by 2032, at a CAGR of 6.98%. This growth is fueled by the increasing global prevalence of surgical procedures, enhancements in healthcare infrastructure, and the rising incidence of chronic diseases and traumatic injuries, which heighten the demand for effective hemostatic solutions. Continuous innovation within the sector is leading to the development of advanced flowable hemostats that are more effective, biocompatible, and easier to use, addressing the needs of modern surgical practices.

The shift towards minimally invasive surgeries, which require precise hemostatic control, further drives the adoption of flowable hemostats across various medical specialties. Key market players like Baxter International, Johnson & Johnson Services, Integra LifeSciences, Pfizer, and Ethicon are spearheading these advancements through strategic R&D investments, product launches, and global partnerships.

Geographically, North America leads the market, supported by its advanced healthcare system and high medical spending, followed by Europe with its increasing surgical volumes and favorable reimbursement policies. The Asia-Pacific region is projected to experience significant growth due to economic advancements, rising healthcare investments, and increasing awareness of advanced medical technologies. Emerging markets in Latin America and the Middle East and Africa also present growth opportunities, driven by governmental healthcare initiatives, rising disposable incomes, and an aging population.

Design Element 2

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

CTA Design Element 3

Market Drivers

Increasing Surgical Procedures:

One of the primary drivers propelling the growth of the flowable hemostats market is the rising number of surgical procedures worldwide. For instance, in 2022, there were approximately 294 million surgical procedure units worldwide. As healthcare infrastructure continues to improve globally, there is a significant uptick in various surgical interventions across different medical specialties such as general surgery, orthopedics, cardiovascular surgery, and neurosurgery, among others. Flowable hemostats play a crucial role in these procedures because they provide effective hemostasis, reduce blood loss, and improve patient outcomes. This increasing volume of surgeries directly translates to a higher demand for flowable hemostats, thereby driving market growth.

Advancements in Hemostatic Technologies:

Another significant market driver is the continuous innovation and advancements in hemostatic technologies. Manufacturers are investing heavily in research and development to introduce new and improved flowable hemostats with enhanced efficacy, safety profiles, and ease of use. For instance, recent advances in hemostatic materials have undergone various iterations by integrating new ideas with old concepts. These innovations often involve the incorporation of advanced biomaterials, such as synthetic polymers or biologically derived agents, that offer superior hemostatic properties while minimizing adverse effects. Additionally, the development of hemostats with targeted applications, such as specific tissue types or surgical procedures, further expands the market by catering to diverse medical needs and preferences.

Growing Geriatric Population and Chronic Conditions:

The demographic trend of an aging population globally contributes significantly to the demand for flowable hemostats. Elderly individuals often undergo surgical interventions for age-related conditions, including cardiovascular diseases, orthopedic disorders, and cancer surgeries. Moreover, the prevalence of chronic illnesses such as diabetes, which can necessitate surgical interventions for complications, adds to the demand for hemostatic agents. As the elderly population continues to grow and chronic disease burdens rise, the need for effective hemostasis solutions during surgeries becomes paramount, thereby driving market growth for flowable hemostats.

Expanding Application Across Healthcare Settings:

The versatility of flowable hemostats in various healthcare settings is another key driver shaping the market landscape. These hemostatic agents find applications not only in traditional operating rooms but also in ambulatory surgical centers, emergency departments, and outpatient clinics. The shift towards minimally invasive procedures and the increasing adoption of advanced hemostatic techniques further broaden the market scope for flowable hemostats. Additionally, the growing emphasis on cost-effective healthcare solutions encourages healthcare providers to utilize flowable hemostats as part of efficient perioperative care strategies, stimulating market growth across different healthcare facilities and settings.

Market Trends

Increasing Surgical Procedures:

The flowable hemostats market is experiencing a surge due to the increasing number of surgical procedures performed globally. For instance, in 2022, there were approximately 294 million surgical procedure units worldwide. As healthcare facilities become more advanced and accessible, there’s a growing demand for hemostatic agents that can effectively control bleeding during surgeries. This trend is particularly prominent in the orthopedic, cardiovascular, and general surgery segments, driving the adoption of flowable hemostats.

Technological Advancements:

Advancements in technology are revolutionizing the flowable hemostat market. Manufacturers are focusing on developing innovative products with improved hemostatic properties, reduced application time, and enhanced safety profiles. For instance, recent advances in hemostatic materials have undergone various iterations by integrating new ideas with old concepts. The integration of biodegradable polymers, nanotechnology, and advanced hemostatic agents is leading to the creation of next-generation flowable hemostats that offer better efficacy and patient outcomes.Growing Geriatric Population:

The aging population worldwide is contributing significantly to the expansion of the flowable hemostats market. Elderly individuals often require surgical interventions for various medical conditions, including cardiovascular diseases, orthopedic injuries, and cancer treatments. Flowable hemostats play a crucial role in managing bleeding complications in these patients, thereby fueling market growth.

Increased Focus on Minimally Invasive Procedures:

There’s a notable shift towards minimally invasive surgical techniques across different medical specialties. These procedures offer benefits such as reduced recovery time, a lower risk of infection, and improved patient comfort. As a result, there’s a growing demand for flowable hemostats that can be easily applied during minimally invasive surgeries, driving market expansion.

Strategic collaborations and partnerships:

Collaboration and partnerships among key players in the healthcare industry are shaping the flowable hemostats market landscape. Companies are entering into strategic alliances to expand their product portfolios, enhance distribution networks, and gain a competitive edge. Moreover, collaborations with research institutions and academic centers are driving R&D efforts to bring innovative flowable hemostatic solutions to the market.

Market Restraints and Challenges

Regulatory Hurdles:

One of the significant challenges facing the Flowable Hemostats Market is navigating the complex regulatory landscape. Health authorities require rigorous testing and approval processes for these medical products, which can lead to delays in market entry and increased costs for manufacturers. Ensuring compliance with evolving regulatory standards across different regions adds another layer of complexity.

Limited Adoption in Developing Regions:

While flowable hemostats offer advanced hemostatic solutions, their adoption remains limited in developing regions due to factors such as high product costs, a lack of awareness among healthcare providers, and inadequate infrastructure. Expanding market penetration in these regions requires targeted strategies to address affordability concerns and educate healthcare professionals about the benefits of these products.

Competition from Alternative Hemostatic Technologies:

The Flowable Hemostats Market faces intense competition from alternative hemostatic technologies such as mechanical hemostats, topical hemostats, and fibrin sealants. Each of these technologies offers unique advantages and may be preferred in certain clinical scenarios, making it challenging for flowable hemostats to establish dominance across all applications.

Risk of Adverse Events:

Like any medical intervention, the use of flowable hemostats carries a risk of adverse events such as allergic reactions, infections, or tissue damage. Healthcare providers must carefully weigh the benefits of hemostasis against the potential risks, and manufacturers must invest in robust safety testing and post-market surveillance to mitigate these concerns and maintain patient trust.

Cost Constraints and Reimbursement Challenges:

Cost considerations are critical in the adoption of flowable hemostats, especially in healthcare systems with stringent budget constraints. Reimbursement policies may vary, leading to uncertainty for providers and patients regarding coverage for these products. Manufacturers must demonstrate the cost-effectiveness of flowable hemostats compared to alternative treatments to secure favorable reimbursement and encourage wider adoption.

Key Players

  • Ethicon, Inc. (Johnson & Johnson)
  • Baxter International, Inc.
  • CR Bard Inc. (Becton, Dickinson, and Company)
  • Pfizer Inc.
  • CryoLife Inc.
  • Integra LifeSciences Corporation
  • B. Braun Melsungen AG
  • Biom’up SA
  • Equimedical Srl
  • Hemostasis, LLC

Recent Developments

  • In January 2023, Medcura, Inc., a prominent biotechnology firm, disclosed that its LifeGel Absorbable Surgical Hemostat had received the ‘Breakthrough Device Designation’ from the U.S. FDA.

Segmentation Analysis

By Material

One crucial segmentation parameter is the material used in flowable hemostats. These materials typically include collagen-based, gelatin-based, and combination-based hemostats. Collagen-based hemostats, derived from animal sources like bovine or porcine, offer excellent biocompatibility and are widely used in surgical procedures. Gelatin-based hemostats, derived from purified animal collagen, are known for their absorbent properties and are often used to control bleeding during surgeries. Combination-based hemostats blend multiple materials to achieve optimal hemostatic properties, catering to specific surgical requirements.

By Application

Another vital segmentation aspect is based on application areas where flowable hemostats find extensive usage. They are commonly utilized in general surgery, cardiovascular surgery, orthopedic surgery, and neurosurgery, among others. In general surgery, flowable hemostats play a crucial role in managing bleeding during various procedures like laparotomy, appendectomy, and cholecystectomy. In cardiovascular surgery, they are used to control bleeding in cardiac procedures such as coronary artery bypass grafting (CABG) and valve replacement surgeries. Orthopedic surgeries benefit from flowable hemostats for managing bleeding in procedures like joint replacements and spinal surgeries. Additionally, neurosurgery relies on these hemostats to achieve hemostasis during delicate brain and spinal cord surgeries.

By End-User

Furthermore, segmentation based on end-users provides insights into the market’s distribution channels and consumer demographics. The end-user segments for flowable hemostats encompass hospitals, ambulatory surgical centers (ASCs), and specialty clinics. Hospitals represent the largest end-user segment, given their extensive surgical services and higher patient footfall. Ambulatory surgical centers, known for their efficiency and cost-effectiveness, are increasingly adopting flowable hemostats due to their ease of use and quick hemostatic action, particularly in outpatient surgical procedures. Specialty clinics focusing on specific medical areas such as cardiology, orthopedics, or neurology also contribute significantly to the demand for flowable hemostats, driven by the need for precise hemostatic control in specialized procedures.

Segmentations

By Material

  • Porcine Gelatin
  • Bovine Gelatin

By Application

  • General Surgery
  • Cardiac Surgery
  • Vascular Surgery
  • Neuro and Spine Surgery
  • Orthopedic Surgery
  • Others

By End-user

  • Hospitals
  • Ambulatory Surgery Centers
  • Clinics

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • The U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • South-east Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Argentina
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of the Middle East and Africa

Regional Analysis

North America:

North America, which leads the market with a substantial 40% share, benefits from advanced healthcare infrastructure and increasing surgical procedures. The United States drives the region’s market dominance with a high prevalence of chronic diseases and a robust healthcare system that encourages the adoption of advanced medical products.

Europe:

Europe boasts a significant 30% share of the Flowable Hemostats Market, demonstrating steady growth. Countries such as Germany, France, and the United Kingdom contribute substantially to this market share due to a growing aging population and rising awareness about innovative medical solutions. The presence of key market players also bolsters Europe’s position in the global market.

Asia Pacific:

Witnessing rapid growth, Asia Pacific accounts for 20% of the market share. Emerging economies such as China, India, and Japan are driving this growth, fueled by increasing investments in healthcare infrastructure and rising disposable income levels. The region’s large patient pool and expanding healthcare facilities create lucrative opportunities for market players.

Latin America:

Latin America’s market share is 8%, indicating steady growth in the Flowable Hemostats Market. Countries like Brazil and Mexico are key contributors, driven by improving healthcare access and a rising number of surgeries. Market penetration in this region is supported by strategic partnerships and expanding distribution networks.

Middle East and Africa:

The Middle East and Africa region, which holds a 2% share, shows promising growth prospects. Factors such as a growing healthcare sector, rising awareness about advanced medical treatments, and government initiatives to enhance healthcare services contribute to the market’s expansion. However, challenges related to infrastructure and regulatory frameworks can impact market penetration.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Future Outlook

  • The flowable hemostats market is poised for substantial growth, driven by advancements in surgical techniques and an increasing number of surgical procedures worldwide.
  • Technological innovations, such as the development of next-generation hemostatic agents with improved efficacy and safety profiles, will contribute significantly to market expansion.
  • Rising demand for minimally invasive surgeries is expected to fuel the adoption of flowable hemostats, as they offer precise application and reduce surgical trauma.
  • The aging population and the corresponding surge in chronic diseases requiring surgical intervention are key factors driving the demand for flowable hemostats in both developed and emerging markets.
  • Collaborations and strategic partnerships between medical device companies and healthcare providers will play a crucial role in enhancing product accessibility and market penetration.
  • Regulatory initiatives aimed at ensuring the safety and efficacy of hemostatic products will continue to shape market dynamics and influence product development strategies.
  • Geographically, North America and Europe are anticipated to dominate the flowable hemostats market, driven by well-established healthcare infrastructure and high adoption rates of advanced surgical technologies.
  • Asia-Pacific is poised for rapid growth, supported by increasing healthcare expenditure, growing awareness about advanced medical treatments, and expanding healthcare access in emerging economies.
  • Market players are focusing on research and development activities to introduce novel formulations and delivery systems that address specific clinical needs, further stimulating market growth.
  • Overall, the flowable hemostats market is expected to witness sustained expansion, propelled by technological innovations, demographic trends, and strategic collaborations, presenting lucrative opportunities for industry stakeholders.

For Table OF Content – Request For Sample Report –

Design Element 2

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

CTA Design Element 3

Frequently Asked Questions:

What is the projected growth of the Flowable Hemostats Market between 2023 and 2032?

The projected growth of the Flowable Hemostats Market between 2023 and 2032 is anticipated to be substantial, with an estimated compound annual growth rate (CAGR) of 6.98% during this period.

What factors are driving the growth of the Flowable Hemostats Market?

Several factors are driving the growth of the Flowable Hemostats Market. These include increasing surgical procedures, advancements in healthcare infrastructure, rising demand for minimally invasive surgeries, and the growing prevalence of chronic diseases, leading to a higher need for hemostatic agents.

Who are the major players in the Flowable Hemostats Market?

The major players in the Flowable Hemostats Market are renowned companies such as Ethicon, Inc. (Johnson & Johnson), Baxter International Inc., and CR Bard, Inc. (Becton, Dickinson, and Company). These companies have established a strong presence in the market through their innovative products, strategic collaborations with healthcare providers, and extensive distribution networks. Their focus on research and development also enables them to offer cutting-edge solutions that meet the evolving needs of healthcare professionals and patients.

How is the availability of the Flowable Hemostats Market expanding, and through what channels?

The availability of Flowable Hemostats Market is expanding through multiple channels to cater to the increasing demand. These channels include traditional distribution channels such as hospitals, clinics, and healthcare institutions where these products are directly supplied to healthcare professionals. Additionally, online platforms and e-commerce channels have gained prominence, offering convenient access to a wide range of flowable hemostats for healthcare facilities and individual consumers. Moreover, collaborations with medical device distributors and partnerships with global healthcare organizations further enhance the market’s reach and availability.

Drug Discovery Market

Published:
Report ID: 38270

United States Medical Tourism Market

Published:
Report ID: 38255

United States Restorative Dentistry Market

Published:
Report ID: 38258

Neurotrophic Keratitis Treatment Market

Published:
Report ID: 33425

Latin America Veterinary Imaging Market

Published:
Report ID: 38233

Japan Artificial Intelligence AI in Medical Diagnostics Market

Published:
Report ID: 38197

Colorectal Cancer (CRC) Market

Published:
Report ID: 37220

US Dental Equipment Market

Published:
Report ID: 37218

AI in Medical Diagnostics Market

Published:
Report ID: 38121

India Insulin Pump Market

Published:
Report ID: 38098

DNA Sequencing Market

Published:
Report ID: 38067

Digital X-Ray Market

Published:
Report ID: 38063

Purchase Options

$2999
Delivery Format: Excel.
$4999
Designed for the individual purchaser.
$6999
Users located at a single corporate site or regional office.
$7999
Allowed for unlimited sharing globally within one company.
Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN